Human Genome Sciences
Human Genome Sciences (HGS) was a biopharmaceutical corporation that specialized in the research and development of novel protein and small molecule drugs. The company was founded in 1992 and was based in Rockville, Maryland, United States. In 2012, HGS was acquired by GlaxoSmithKline (GSK), a British multinational pharmaceutical company.
History[edit | edit source]
HGS was established in 1992 by William A. Haseltine, a renowned scientist in the field of genomics. The company was one of the pioneers in the use of human genome sequencing for drug discovery. In its early years, HGS collaborated with several other companies and academic institutions to identify and patent thousands of human genes.
In 2003, HGS received its first product approval from the Food and Drug Administration (FDA) for Syncria, a drug used for the treatment of Type 2 diabetes. This was followed by the approval of Benlysta, a drug for the treatment of lupus, in 2011.
In 2012, HGS was acquired by GlaxoSmithKline for $3.6 billion. The acquisition was part of GSK's strategy to strengthen its portfolio of innovative pharmaceuticals.
Research and Development[edit | edit source]
HGS's research and development efforts were focused on the discovery of novel protein and small molecule drugs. The company used a variety of techniques, including genomics, proteomics, and bioinformatics, to identify potential drug targets.
One of the company's most significant achievements was the development of Benlysta, the first new drug for lupus in over 50 years. Benlysta works by inhibiting the activity of B-lymphocyte stimulator (BLyS), a protein that stimulates the production of autoantibodies in lupus patients.
Impact[edit | edit source]
The work of HGS has had a significant impact on the field of genomics and drug discovery. The company's approach to using human genome sequencing for drug discovery has been adopted by many other biopharmaceutical companies. Furthermore, the development of Benlysta has provided a new treatment option for lupus patients, improving their quality of life.
See Also[edit | edit source]
References[edit | edit source]
 | This biotechnology article is a stub. You can help WikiMD by expanding it. |
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
